SolasCure selected for innovate UK global incubator programme in houston

FHS
June 3, 2024
10:41 am

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US.

(Favezelimab + pembrolizumab) by Merck for Bladder Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 5, 2023

Even Modest Lp(a) Elevations Bode Poorly for Cardiovascular Health

Lipoprotein(a), or Lp(a), at levels well below currently accepted risk thresholds correlated with increased cardiovascular risk in a large registry study, suggesting a wider patient

February 27, 2024

Columbia Care Q2 Revenue Increases 4% Sequentially to $129.2 Million

Columbia Care Reports Second Quarter 2023 Results NEW YORK–(BUSINESS WIRE), August 14, 2023–Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the

August 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.